Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Response to Treatment
100%
MicroRNA
100%
Clinical Validation
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Response Predictors
100%
Second-line Treatment
66%
R-CHOP
33%
Third-line Treatment
33%
Clinical Response
16%
Gene Expression
16%
Outcome Prediction
16%
Large Cohort
16%
Growth Inhibition
16%
Cancer Cell Lines
16%
Cyclophosphamide
16%
International Prognostic Index
16%
Lymphoma Patients
16%
Poor Responders
16%
Drug Combination
16%
MicroRNA Expression
16%
Sensitivity Method
16%
Etoposide
16%
Non-responders
16%
Diagnostic Biopsy
16%
Post-transcriptional Level
16%
CHOEP
16%
NCI-60
16%
Doxorubicine
16%
Prediction Analysis
16%
Treatment Lines
16%
FFPE Tissue
16%
Short Non-coding RNA
16%
De Novo Diffuse Large B-cell Lymphoma
16%
Neuroscience
MicroRNA
100%
B Cell
100%
CHOP
42%
Cell Line
28%
Gene Expression
14%
Cyclophosphamide
14%
Combination Drug
14%
Non-Coding RNA
14%
Vincristine
14%
Etoposide
14%
Doxorubicin
14%
Immunology and Microbiology
B Cell
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
66%
Gene Expression
33%
Cell Line
33%
Cyclophosphamide
33%
Cancer Cell Line
33%
Growth Inhibition
33%
Ribonucleic Acid
33%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
microRNA
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Malignant Neoplasm
14%
Cyclophosphamide
14%
Doxorubicin
14%
Combination Drug
14%
Vincristine
14%
Etoposide
14%
Untranslated RNA
14%
Biochemistry, Genetics and Molecular Biology
MicroRNA
100%
B Cell
100%
Gene Expression
14%
Growth Inhibition
14%
Cancer Cell
14%
Non-Coding RNA
14%
Cyclophosphamide
14%
Doxorubicin
14%